122 related articles for article (PubMed ID: 36725382)
1. Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer.
Patel SA; Liu Y; Solanki AA; Baumann BC; Efstathiou JA; Jani AB; Chang AJ; Fischer-Valuck B; Royce TJ
Urol Oncol; 2023 Jul; 41(7):325.e15-325.e23. PubMed ID: 36725382
[TBL] [Abstract][Full Text] [Related]
2. Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Royce TJ; Liu Y; Milowsky MI; Efstathiou JA; Jani AB; Fischer-Valuck B; Patel SA
Clin Genitourin Cancer; 2021 Aug; 19(4):362-368. PubMed ID: 33839040
[TBL] [Abstract][Full Text] [Related]
3. Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?
Andruska N; Waters MR; Fischer-Valuck BW; Smith ZL; Kim EH; Reimers M; Brenneman R; Gay HA; Patel SA; Michalski JM; Delacroix SE; Efstathiou JA; Baumann BC
Clin Genitourin Cancer; 2023 Dec; 21(6):653-659.e1. PubMed ID: 37704483
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
7. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
8. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
9. Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer.
Kotha NV; Kumar A; Nelson TJ; Qiao EM; Qian AS; Voora RS; McKay RR; Rose BS; Stewart TF
Urol Oncol; 2022 Jun; 40(6):274.e1-274.e6. PubMed ID: 35216893
[TBL] [Abstract][Full Text] [Related]
10. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of robot-assisted vs. open radical cystectomy.
Hanna N; Leow JJ; Sun M; Friedlander DF; Seisen T; Abdollah F; Lipsitz SR; Menon M; Kibel AS; Bellmunt J; Choueiri TK; Trinh QD
Urol Oncol; 2018 Mar; 36(3):88.e1-88.e9. PubMed ID: 29277584
[TBL] [Abstract][Full Text] [Related]
12. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
13. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.
Fischer-Valuck BW; Rao YJ; Henke LE; Rudra S; Hui C; Baumann BC; Gay HA; Michalski JM
Eur Urol Focus; 2018 Dec; 4(6):900-906. PubMed ID: 28919521
[TBL] [Abstract][Full Text] [Related]
15. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.
Ritch CR; Balise R; Prakash NS; Alonzo D; Almengo K; Alameddine M; Venkatramani V; Punnen S; Parekh DJ; Gonzalgo ML
BJU Int; 2018 May; 121(5):745-751. PubMed ID: 29281848
[TBL] [Abstract][Full Text] [Related]
16. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
17. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.
Audenet F; Waingankar N; Ferket BS; Niglio SA; Marqueen KE; Sfakianos JP; Galsky MD
J Urol; 2018 Nov; 200(5):996-1004. PubMed ID: 29879397
[TBL] [Abstract][Full Text] [Related]
19. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience.
Tunio MA; Hashmi A; Qayyum A; Mohsin R; Zaeem A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e457-62. PubMed ID: 21945107
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
